Heart scan showdown: new PET agent vs. standard SPECT in borderline blockages

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1.Male or female participants aged 18 years or older. * 2.Suspected or known stable coronary artery disease with related symptoms and stable condition, and having at least one coronary artery disease risk factor, including: hypertension, hyperlipidemia, diabetes, obesity, alcohol abuse, smoking, family history of coronary artery disease, postmenopausal status in women, or advanced age. * 3.Underwent coronary CTA within the past 6 months showing 30%-90% stenosis, or indicating mild to moderate-to-severe stenosis. * 4.Able to communicate effectively with the investigators, understand and comply with the clinical study requirements, voluntarily participate in the study, and provide written informed consent. Exclusion Criteria: * 1\. Patients with a history of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). * 2.Patients with a prior diagnosis of myocardial infarction, congenital heart disease, cardiomyopathy, myocarditis, or other cardiac diseases. * 3.Patients known to have severe allergic reactions to alcohol. * 4.Patients known to have an allergy or other contraindications to adenosine. * 5.Patients known to be allergic to iodinated contrast agents. * 6.Individuals with significant occupational exposure to ionizing radiation within the past 10 years (e.g., exceeding 50 mSv/year), or exposure to radioactive substances or ionizing radiation for therapeutic or research purposes. * 7.Men and women of childbearing potential who do not plan to use effective contraception during the study and for 6 months after study completion (effective methods include sterilization, intrauterine hormonal devices, condoms, contraceptive pills/agents, abstinence, or partner vasectomy/tubal ligation). * 8.Pregnant or lactating women. * 9.Patients with claustrophobia, bipolar disorder, other psychiatric disorders, or poor compliance. * 10.Patients who participated in another investigational drug clinical study within 30 days prior to enrollment or plan to do so during follow-up. * 11.Any other condition that, in the opinion of the investigators, makes the patient unsuitable for participation.